Article Information
History
- May 11, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Michael Maes, M.D., Ph.D.a,b,c,*,
- Laura Andrés-Rodríguezd,
- Aristo Vojdani, Ph.D.e,f,g,
- Sunee Sirivichayakul, Ph.D.h,
- Decio S. Barbosa, Ph.D.i and
- Buranee Kanchanatawan, M.D.a
- aDepartment of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- bDepartment of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria
- cIMPACT Strategic Research Center, Deakin University, Geelong, Australia
- dGroup of Psychological Research in Fibromyalgia & Chronic Pain (AGORA), Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain
- eImmunosciences Lab., Inc, Los Angeles, CA, USA
- fCyrex Labs, LLC, Phoenix, AZ, USA
- gDepartment of Preventive Medicine, Loma Linda University, Loma Linda, CA, USA
- hFaculty of Medicine, Chulalongkorn University, Bangkok, Thailand
- iHealth Sciences Graduate Program, Health Sciences Center, State University of Londrina, Londrina, PR, Brazil
- ↵*Corresponding author: Prof. Dr. Michael Maes, M.D., Ph.D., IMPACT Strategic Research Center, Barwon Health, Deakin University, Geelong, Vic, Australia, dr.michaelmaes{at}hotmail.com, https://scholar.google.co.th/citations?user=1wzMZ7UAAAAJ&hl=th&oi=ao
Posted May 11, 2021.
In schizophrenia, chronic fatigue syndrome- and fibromyalgia-like symptoms are driven by breakdown of the paracellular pathway with increased zonulin and immune activation-associated neurotoxicity
